Clinical Trials on T-cell Large Granular Lymphocytic Leukemia

Total 2391 results

Sidney Kimmel Cancer Center at Thomas Jefferson...
American Society of Clinical Oncology

Completed

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoid Malignancies (New or Relapsed) | Adult T-cell Leukemia/Lymphoma

United States
Hoffmann-La Roche

Completed

An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia

Lymphocytic Leukemia, Chronic

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
National Cancer Institute (NCI)

Completed

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Refractory Chronic Lymphocytic Leukemia

United States
Ohio State University Comprehensive Cancer Center
Astex Pharmaceuticals, Inc.

Completed

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

B-Chronic Lymphocytic Leukemia

United States
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
M.D. Anderson Cancer Center
Pharmacyclics LLC.

Completed

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Cyclacel Pharmaceuticals, Inc.

Terminated

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Lymphoma | Leukemia
Hebei Senlang Biotechnology Inc., Ltd.

Active, not recruiting

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

China
University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
BeiGene

Completed

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma

China
Janssen Pharmaceutical K.K.

Completed

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphocytic Leukemia

Japan
National Cancer Institute (NCI)

Completed

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

Leukemia | Chronic | Lymphocytic

United States
University Hospital, Clermont-Ferrand
Pierre Fabre Laboratories

Unknown

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia (RICAC)

Chronic Lymphocytic Leukemia | Lymphocytic Lymphoma

France
Exelixis

Terminated

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Sorrento Therapeutics, Inc.

Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Diffuse Large B Cell Lymphoma | Biliary Tract Cancer | Peripheral T Cell Lymphoma | Extranodal NK T Cell Lymphoma, Nasal
Dana-Farber Cancer Institute
TG Therapeutics, Inc.; The Leukemia and Lymphoma Society; Blood Cancer Research...

Completed

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Therapeutic Advances in Childhood Leukemia Consortium

Terminated

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia | Precursor T-Cell Lymphoblastic Leukemia

United States, Australia
Spectrum Pharmaceuticals, Inc

Completed

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Canadian Cancer Trials Group
Celgene

Completed

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Peripheral T-Cell Lymphoma

Canada
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; SWOG Cancer Research...

Completed

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Medical College of Wisconsin

Recruiting

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Follicular Lymphoma | Multiple Myeloma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic | Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Lymphomas Non-Hodgkin's B-Cell

United States
M.D. Anderson Cancer Center
Loxo Oncology, Inc.; The Leukemia and Lymphoma Society

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Leukemia

United States
Brown University

Terminated

Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma (273)

Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Burkitts Lymphoma | T Cell Lymphomas | Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myeloproliferative Neoplasm | Relapsed Follicular Lymphoma | Relapsed T-Cell Lymphoma and other conditions

United States
St. Jude Children's Research Hospital
Novartis Pharmaceuticals; Spectrum Pharmaceuticals, Inc

Terminated

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Acute Lymphoblastic Leukemia | Leukemia, B-Cell | Leukemia, T-Cell | Lymphoma, Non-Hodgkin's

United States
Emory University
Novartis

Terminated

Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Medical College of Wisconsin
Miltenyi Biomedicine GmbH

Active, not recruiting

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
University of California, San Diego
Memgen, LLC

Completed

Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Januario Castro, M.D.
FDA Office of Orphan Products Development; Memgen, LLC

Terminated

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Fred Hutchinson Cancer Center

Completed

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

United States
BeiGene

Recruiting

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma | Leukemia | Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

China
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Recurrent Chronic Lymphocytic Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT)

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Non Hodgkin's Lymphoma

United States
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom
Beijing Boren Hospital

Recruiting

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Relapse/Recurrence | T-cell Leukemia/Lymphoma | Refractory T Lymphoblastic Leukemia/Lymphoma

China
Jennifer R. Brown, MD, PhD
AstraZeneca; TG Therapeutics, Inc.

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed Chronic Lymphocytic Leukemia

United States
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell, Peripheral | Lymphoma, Large-Cell, Anaplastic | Lymphoma, Extranodal NK-T-Cell | Enteropathy-Associated T-Cell Lymphoma

United States
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

China

Clinical Trials on T-cell Large Granular Lymphocytic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations